NVision Imaging Technologies

company

About

Quantum MRI agents for assessing early patient response to treatment at the metabolic level

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$2.40M
Industries
Biopharma,Biotechnology,Health Care,Health Diagnostics,Medical,Medical Device,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
11 - 50
Operating Status
Active

NVision has developed a platform which polarizes natural metabolites, enabling these safe molecules to be used as an agent for imaging tumor metabolism via MRI. This technology will allow clinicians to quickly determine which patients are responding to cancer therapies, allowing non-responders to be moved onto another line of therapy more quickly. The company was founded in 2015 and is based in Ulm, Germany.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$2.40M
NVision Imaging Technologies has raised a total of $2.40M in funding over 2 rounds. Their latest funding was raised on Aug 1, 2021 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 1, 2021 Grant $2.40M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
NVision Imaging Technologies is funded by 1 investors. Invest BW are the most recent investors.
Investor Name Lead Investor Funding Round
Invest BW Grant